Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS • Currently down 35.79 (-4.54%) in today's trading session

15 members of Congress have disclosed 81 trades in Regeneron Pharmaceuticals, Inc. (REGN) via STOCK Act filings. The most recent disclosure was a sale by Gilbert Cisneros on 15 May 2026. The most active traders have been Donald S. Beyer (13), Sheldon Whitehouse (12), and Thomas R. Suozzi (11). Aggregate disclosed activity totals roughly $512.5K in purchases and $674.5K in sales (midpoint estimates from bracketed disclosure amounts).

Regeneron Pharmaceuticals, Inc. is currently trading at $752.25, positioned at 66% of its 52-week range ($541.00 – $859.34).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$752.25
24h Change
-35.79 (-4.54%)
52 Week Range
$541.00–$859.34
View on NASDAQ

Regeneron Pharmaceuticals, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for REGN

Select to highlight on chart
5 transactions
Compliance: 71%
Gilbert Cisneros15 May 20268 Jun 2026SaleStock$1,001 - $15,000N/A
Julia Letlow12 Feb 202612 Mar 2026PurchaseStock$1,001 - $15,000-3.43%
Gilbert Cisneros18 Nov 202515 Dec 2025PurchaseStock$1,001 - $15,000+6.81%
Robert P. Bresnahan15 May 20259 Jun 2025PurchaseStock$1,001 - $15,000N/A
Byron Donalds10 Apr 202524 May 2025SaleStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$77.5B

Volume

1.07M

Beta

0.24

P/E Ratio

16.49

Fundamentals

EPS

$45.63

Div. Yield

0.49%

Open

$771.84

Day Range

$750.00 – $777.07

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Leonard S. Schleifer
IPO Date
1991-04-02
Website
www.regeneron.com

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA,...

Earnings

Next Report

Q3 2026

30 Oct

EPS Est.

$15.99

Rev. Est.

$4.5B

Days Until

32

Recent Quarters

Q2 202630 Jul
EPS$14.29
Beat 40.6%
Q1 202629 Apr
EPS$9.47
Beat 6.3%
Q4 202530 Jan
EPS$11.44
Beat 6.5%
Q3 202528 Oct
EPS$11.83
Beat 22.6%
Q2 20251 Aug
EPS$12.89
Beat 52.9%
Q1 202529 Apr
EPS$8.22
Miss 4.6%
Q4 20244 Feb
EPS$12.07
Beat 7.7%
Q3 202431 Oct
EPS$12.46
Beat 6.6%
Q2 20241 Aug
EPS$11.56
Beat 8.9%
Q1 20242 May
EPS$9.55
Miss 6.1%
Q4 20232 Feb
EPS$11.86
Beat 10.5%
Q3 20232 Nov
EPS$11.59
Beat 8.1%
Q2 20233 Aug
EPS$10.24
Beat 4.1%
Q1 20234 May
EPS$10.09
Beat 9.1%
Q4 20223 Feb
EPS$12.56
Beat 25.2%
Q3 20223 Nov
EPS$11.14
Beat 17.5%
Q2 20223 Aug
EPS$9.77
Beat 14.5%
Q1 20224 May
EPS$8.93
Miss 8.3%
Q4 20214 Feb
EPS$21.32
Beat 16.2%
Q3 20214 Nov
EPS$14.37
Beat 42.3%
Q2 20215 Aug
EPS$25.80
Beat 47.2%
Q1 20216 May
EPS$9.89
Beat 9.9%
Q4 20205 Feb
EPS$9.53
Beat 13.6%
Q3 20205 Nov
EPS$8.36
Beat 17.1%
Q2 20205 Aug
EPS$7.16
Beat 19.7%
Q1 20205 May
EPS$6.60
Beat 7.7%
Q4 20196 Feb
EPS$7.50
Beat 8.5%
Q3 20195 Nov
EPS$6.67
Beat 4.9%
Q2 20196 Aug
EPS$6.02
Beat 11.1%
Q1 20197 May
EPS$4.45
Miss 18.6%
Q4 20186 Feb
EPS$6.84
Beat 22.1%
Q3 20186 Nov
EPS$5.87
Beat 14.4%
Q2 20182 Aug
EPS$5.45
Beat 16.0%
Q1 20183 May
EPS$4.67
Beat 7.4%
Q4 20178 Feb
EPS$5.23
Beat 11.8%
Q3 20178 Nov
EPS$3.99
Beat 3.6%
Q2 20173 Aug
EPS$4.17
Beat 31.6%
Q1 20174 May
EPS$2.92
Miss 4.6%
Q4 20169 Feb
EPS$3.04
Beat 0.3%
Q3 20164 Nov
EPS$3.13
Beat 15.5%
Q2 20164 Aug
EPS$2.82
Beat 6.4%
Q1 20165 May
EPS$2.57
Beat 2.8%
Q4 20159 Feb
EPS$2.83
Miss 15.0%
Q3 20154 Nov
EPS$3.47
Beat 11.6%
Q2 20154 Aug
EPS$2.89
Beat 7.8%
Q1 20157 May
EPS$2.88
Beat 1.1%
Q4 201410 Feb
EPS$2.79
Miss 1.4%
Q3 20144 Nov
EPS$2.52
Miss 2.3%
Q2 20145 Aug
EPS$2.47
Beat 6.5%
Q1 20148 May
EPS$2.26
Beat 128.3%
Q4 201311 Feb
EPS$2.24
Beat 119.6%
Q3 20135 Nov
EPS$2.40
Beat 142.4%
Q2 20136 Aug
EPS$1.73
Beat 101.2%
Q1 20133 May
EPS$1.78
Beat 67.9%
Q4 201214 Feb
EPS$1.47
Beat 37.4%
Q3 201224 Oct
EPS$1.72
Beat 81.0%
Q2 201225 Jul
EPS$0.70
Beat 159.3%
Q1 201226 Apr
EPS$0.16
Beat 169.6%
Q4 201113 Feb
EPS$-0.54
Beat 10.0%
Q3 201127 Oct
EPS$-0.68
Beat 10.5%
Q2 201128 Jul
EPS$-0.69
Miss 68.3%
Q1 20113 May
EPS$-0.49
Miss 36.1%
Q4 201017 Feb
EPS$-0.17
Beat 46.9%
Q3 201028 Oct
EPS$-0.41
Miss 20.6%
Q2 201028 Jul
EPS$-0.31
Beat 16.2%
Q1 201029 Apr
EPS$-0.38
Beat 22.4%
Q4 200918 Feb
EPS$-0.46
Miss 35.3%
Q3 20093 Nov
EPS$-0.01
Beat 94.0%
Q2 20094 Aug
EPS$-0.19
Beat 32.1%
Q1 200930 Apr
EPS$-0.22
Beat 29.0%
Q4 200826 Feb
EPS$-0.40
Miss 33.3%
Q3 20084 Nov
EPS$-0.27
Beat 15.6%
Q2 200831 Jul
EPS$-0.23
Beat 23.3%
Q1 20081 May
EPS$-0.15
Beat 53.1%
Q4 200727 Feb
EPS$-0.19
Beat 59.6%
Q3 20076 Nov
EPS$-0.54
Miss 80.0%
Q2 20071 Aug
EPS$-0.41
Beat 4.7%
Q1 20072 May
EPS$-0.46
Beat 8.0%
Q4 20061 Mar
EPS$-0.51
Beat 0.0%
Q3 20066 Nov
EPS$-0.48
Beat 14.3%
Q2 20063 Aug
EPS$-0.41
Beat 26.8%
Q1 20063 May
EPS$-0.36
Beat 41.0%
Q4 200524 Feb
EPS$-0.53
Beat 18.5%
Q3 20053 Nov
EPS$-0.52
Beat 11.9%
Q2 20054 Aug
EPS$-0.38
Beat 25.5%
Q1 200528 Apr
EPS$-0.07
Beat 75.0%
Q4 200422 Feb
EPS$0.05
Beat 113.9%
Q3 200428 Oct
EPS$-0.20
Beat 50.0%
Q2 200426 Jul
EPS$-0.26
Beat 13.3%
Q1 200426 Apr
EPS$1.06
Beat 330.4%
Q4 200323 Feb
EPS$-0.35
Beat 34.0%
Q3 200329 Oct
EPS$-0.52
Beat 3.7%
Q2 20031 Aug
EPS$-0.58
Beat 3.3%
Q1 20035 May
EPS$-0.68
Beat 20.0%
Q4 200230 Jan
EPS$-0.81
Beat 4.7%
Q3 200231 Oct
EPS$-0.75
Beat 3.9%
Q2 200230 Jul
EPS$-0.69
Miss 7.8%
Q1 200229 Apr
EPS$-0.58
Beat 6.5%
Q4 200131 Jan
EPS$-0.65
Miss 4.8%
Q3 200122 Oct
EPS$-0.46
Beat 16.4%
Q2 200131 Jul
EPS$-0.34
Beat 34.6%
Q1 20011 May
EPS$-0.35
Beat 18.6%
Q4 200025 Jan
EPS$-0.23
Beat 32.4%
Q3 200024 Oct
EPS$-0.09
Beat 70.0%
Q2 200027 Jul
EPS$-0.08
Beat 38.5%
Q1 200028 Apr
EPS$-0.23
Miss 91.7%
Q4 19994 Feb
EPS$-0.04
Beat 81.0%
Q3 199928 Oct
EPS$-0.16
Beat 20.0%
Q2 19995 Aug
EPS$-0.25
Q2 199930 Jul
EPS$-0.25
Beat 0.0%
Q4 199829 Mar
EPS$-0.18
Q3 19985 Nov
EPS$-0.04
Q2 199814 Aug
EPS$0.07
Q1 199814 May
EPS$-0.12
Q4 199726 Mar
EPS$0.02
Q3 199714 Nov
EPS$-0.06
Q2 19971 Aug
EPS$-0.16
Beat 23.8%
Q1 19976 May
EPS$-0.23
Beat 39.5%
Q4 19965 Feb
EPS$-0.32
Beat 3.0%
Q3 199623 Oct
EPS$-0.35
Miss 2.9%
Q2 199629 Jul
EPS$-0.31
Beat 22.5%
Q1 19963 May
EPS$-0.35
Beat 2.8%
Q4 19955 Feb
EPS$-0.38
Miss 26.7%
Q3 199514 Nov
EPS$-0.32
Beat 17.9%
Q2 19951 Aug
EPS$-0.22
Beat 8.3%
Q1 19953 May
EPS$-0.22
Beat 37.1%
Q4 199413 Feb
EPS$-0.30
Beat 23.1%
Q3 199431 Oct
EPS$-0.21
Beat 41.7%
Q2 19943 Aug
EPS$-0.54
Beat 6.9%
Q1 199429 Apr
EPS$-0.57
Beat 6.6%
Q4 199328 Jan
EPS$-0.61
Beat 4.7%
Q3 199329 Oct
EPS$-0.58
Beat 6.5%
Q2 199323 Jul
EPS$-0.61
Miss 8.9%
Q1 199330 Apr
EPS$-0.61
Miss 29.8%
Q4 199225 Jan
EPS$-0.42
Beat 0.0%
Q3 199231 Dec
EPS$-0.42
Q1 199230 Jun
EPS$-0.24
Q4 199131 Mar
EPS$-0.21
Q3 199131 Dec
EPS$-0.14
Q2 199130 Sept
EPS$-0.06
Q1 199130 Jun
EPS$-0.02
Q4 199031 Mar
EPS$-0.07
Q3 199031 Dec
EPS$-0.05
Q2 199030 Sept
EPS$-0.16
Q1 199030 Jun
EPS$-0.16
Q4 198931 Mar
EPS$-0.15

28 politicians traded within 30 days

Dividends

Dividend History

18 Aug 2026
Amount $0.9400
20 May 2026
Amount $0.9400
20 Feb 2026
Amount $0.9400
20 Nov 2025
Amount $0.8800
18 Aug 2025
Amount $0.8800
20 May 2025
Amount $0.8800
20 Feb 2025
Amount $0.8800

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

MSFT

Microsoft Corporation

55
$509.22-6.95 (-1.35%)
Technology
3 politicians hold this stock
$35M in total holdings
3 politicians
View Stock

AAPL

Apple Inc.

50
$338.40-2.67 (-0.78%)
Technology
4 politicians hold this stock
Significant holdings value
4 politicians
View Stock

NVDA

NVIDIA Corporation

48
$228.86+3.79 (+1.68%)
Technology
4 politicians hold this stock
Significant holdings value
4 politicians
View Stock

Frequently Asked Questions about REGN

Which members of Congress have traded REGN?
15 members of Congress have disclosed 81 trades in Regeneron Pharmaceuticals, Inc. (REGN) under the STOCK Act. The most active traders are Donald S. Beyer, Sheldon Whitehouse, and Thomas R. Suozzi.
When was REGN most recently disclosed by Congress?
The most recent REGN disclosure was a sale by Gilbert Cisneros on 15 May 2026.
What is the total disclosed congressional trading volume for REGN?
Members of Congress have disclosed approximately $512.5K in REGN purchases and $674.5K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in REGN?
This REGN page updates as soon as new STOCK Act disclosures are filed for Regeneron Pharmaceuticals, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.